Not Signed In -
Olanzapine Disintegrating Tablets |
Zyprexa Zydis Injection |
Clinical Trial: A Multicenter, Open-Label Trial to Assess Subject Preference of PARCOPA, Carbidopa/Levodopa Orally Disintegrating Tablets, Compared to Conventional Carbidopa/Levodopa Tablets in Subjects with Stable Parkinson''s Disease
A Multicenter, Open-Label Trial to Assess Subject Preference of PARCOPA, Carbidopa/Levodopa Orally Disintegrating Tablets, Compared to Conventional Carbidopa/Levodopa Tablets in Subjects with Stable Parkinson’s Disease
This study has been completed.
|
Purpose
The objective of this trial was to assess subject preference for PARCOPA, carbidopa/levodopa Orally Disintegrating Tablets (ODT), compared with conventional carbidopa/levodopa tablets, in subjects with stable Parkinson’s disease.
| Condition | Intervention | Phase |
|---|---|---|
| Parkinson’s Disease | Drug: PARCOPA | Phase III |
MedlinePlus consumer health information
Study Type: Interventional
Study Design: Randomized, Open Label, Dose Comparison, Crossover Assignment
Eligibility
Ages Eligible for Study: 18 Years and above, Genders Eligible for Study: Both
Criteria
Inclusion Criteria:
- Stable Parkinson’s Disease
Exclusion Criteria:
- Not using carbidopa/levodopa tablets
Location Information
Wisconsin
Schwarz, Mequoin, Wisconsin, United States
Study chairs or principal investigators
Patricia Witt, Study Director, Schwarz Pharma
More Information
Study ID Numbers: SP780
Last Updated: August 30, 2005
Record first received: August 29, 2005
ClinicalTrials.gov Identifier: NCT00139867
Health Authority: United States: Institutional Review Board
ClinicalTrials.gov processed this record on 2005-09-13
Last Updated: August 30, 2005
Record first received: August 29, 2005
ClinicalTrials.gov Identifier: NCT00139867
Health Authority: United States: Institutional Review Board
ClinicalTrials.gov processed this record on 2005-09-13
email this page
print this page
bookmark this page
feedback on this page
